Coherus BioSciences

REDWOOD CITY, Calif., 2014-12-08 15:00 CET (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the 33^rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 9:30 a.m. PT at the Westin St. Francis Hotel in San Francisco, CA.

A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at http://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.

CONTACT:	Jean-Frédéric Viret, Ph.D.
	Chief Financial Officer
	Coherus BioSciences, Inc.
	jviret@coherus.com
	1 (800) 794-5434